BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines total Share-Based Compensation Expense ($M) ($M)
Form 10-Q / 10-K Share-Based Compensation Note (XBRL)
Latest, Q2 2026
138
Period ended Jun 30, 2026
Change on a year earlier
-8.7%
151 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
34
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Share-Based Compensation Expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 138 | -8.7% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 123 | +29.1% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 124 | +14.6% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 141 | +22.9% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 151 | +15.2% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 95.5 | +7.7% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | 108 | +16.2% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 115 | +19.3% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 131 | +26.5% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 88.7 | +17.6% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 92.8 | +18.8% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2023 | Sep 30, 2023 | 96.1 | +22.9% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 103 | +27.1% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 75.4 | +14.9% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 78.1 | +24.0% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2022 | Sep 30, 2022 | 78.2 | +16.5% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 81.3 | +25.5% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 65.6 | +43.2% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 63 | +27.3% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2021 | Sep 30, 2021 | 67.1 | +33.4% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | 64.8 | +42.4% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 45.8 | +19.6% | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2020 | Dec 31, 2020 | 49.5 | +29.2% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2020 | Sep 30, 2020 | 50.3 | +36.7% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 45.5 | +39.6% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 38.3 | +45.1% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 38.3 | +47.3% | Form 10-K (filed 2022-02-28) ↗ |
| Q3 2019 | Sep 30, 2019 | 36.8 | +46.6% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 32.6 | +75.3% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 26.4 | +51.7% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 26 | +57.6% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2018 | Sep 30, 2018 | 25.1 | +88.7% | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2018 | Jun 30, 2018 | 18.6 | +162.0% | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2018 | Mar 31, 2018 | 17.4 | +190.0% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2017 | Dec 31, 2017 | 16.5 | +323.1% | Form 10-K (filed 2020-03-02) ↗ |
| Q3 2017 | Sep 30, 2017 | 13.3 | +375.0% | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2017 | Jun 30, 2017 | 7.10 | +446.2% | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2017 | Mar 31, 2017 | 6 | +130.8% | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2016 | Dec 31, 2016 | 3.90 | +77.3% | Form 10-K (filed 2019-02-28) ↗ |
| Q3 2016 | Sep 30, 2016 | 2.80 | -41.7% | 10-Q FY2016 (XBRL) ↗ |
| Q2 2016 | Jun 30, 2016 | 1.30 | +44.4% | 10-Q FY2016 (XBRL) ↗ |
| Q1 2016 | Mar 31, 2016 | 2.60 | +13.0% | 10-Q FY2016 (XBRL) ↗ |
| Q4 2015 | Dec 31, 2015 | 2.20 | – | Form 10-K (filed 2018-02-28) ↗ |
| Q3 2015 | Sep 30, 2015 | 4.80 | – | 10-Q FY2015 (XBRL) ↗ |
| Q2 2015 | Jun 30, 2015 | 0.90 | – | 10-Q FY2015 (XBRL) ↗ |
| Q1 2015 | Mar 31, 2015 | 2.30 | – | 10-Q FY2015 (XBRL) ↗ |
Breakdown
What makes up total share-based compensation expense ($m)
- Share-Based Compensation — Research & Development ($M)58.5 · Q2 2026
- Share-Based Compensation — Selling, General & Administrative ($M)78.9 · Q2 2026
- Share Options Outstanding at Year-End (M options)–
- Share Options Outstanding — Weighted-Average Exercise Price ($/sh)–
- Share Options Granted During Year (M options)–
- Share Options Granted — Weighted-Average Grant-Date Fair Value ($/sh)–
- Share Options Exercised During Year (M shares)–
- Total Intrinsic Value of Share Options Exercised ($M)–
- Share Options Forfeited / Cancelled During Year (M options)–
- Total Fair Value of Share Options Vested During Year ($M)–
Cite this data
StockData. (2026). BeOne Medicines Total Share-Based Compensation Expense ($M) ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/sbc_tot
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.